2Curex Q2 ’21: Expanding the product portfolio - Redeye

Redeye comments on 2cureX’s Q2 2021 report, with the company continually taking required steps toward IndiTreat commercialization. The company aims to expand its portfolio and launch multiple IndiTreat products for each cancer entity. We are encouraged by the company’s ambitions and see great potential for IndiTreat going forward.

Länk till analysen i sin helhet: https://www.redeye.se/research/819659/2curex-q2-21-expanding-the-product-portfolio?utm_source=finwire&utm_medium=RSS